1. New immunotherapy to target blood cancers, solid tumors

    New immunotherapy to target blood cancers, solid tumors

    A new joint project will develop precision medicines for blood cancers and solid tumors by utilizing immunotherapies targeting natural killer (NK) cells.

    In collaboration between Yissum, the technology-transfer company of the Hebrew University of Jerusalem, biopharmaceutical company Cytovia Therapeutics will sponsor a research program to develop multi-specific antibodies targeting both NK cells and the tumor antigen.

    The research will be led by Hebrew University Prof. Ofer Mandelboim.

    Read Full Article
  1. Categories

    1. News:

      News, Placeholder

    1. Preclinical studies have demonstrated that these multifunctional engagers have the potential for better tumor control without hurting the healthy cells.  For patients and doctors alike, this precision medicine could become the optimal way to treat cancer.
  3. Topics Mentioned